scholarly journals PD46-06 HOSPITAL SAFETY NET BURDEN IDENTIFIES DISPARITIES IN NON-DEFINITIVE MANAGEMENT AND SURVIVAL IN HIGH RISK LOCALIZED PROSTATE CANCER

2021 ◽  
Vol 206 (Supplement 3) ◽  
Author(s):  
Raj Bhanvadia ◽  
Fady Baky ◽  
Michael Chandra ◽  
Alex Kenigsberg ◽  
Yair Lotan ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Safety Net ◽  
Localized Prostate Cancer ◽  
Hospital Safety ◽  
Definitive Management

PO-1196: long term results with moderately hypofractionated RT in high-risk localized prostate cancer.

2020 ◽  
Vol 152 ◽  
pp. S630
Author(s):  
S. Maulik ◽  
I. Mallick ◽  
M. Arunsingh ◽  
S. Chatterjee ◽  
R. Achari ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Localized Prostate Cancer ◽  
Long Term Results

scholarly journals Hypofractionated radiotherapy versus conventional radiotherapy in patients with intermediate- to high-risk localized prostate cancer: a meta-analysis of randomized controlled trials

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Wei Guo ◽  
Yun-Chuan Sun ◽  
Jian-Qiang Bi ◽  
Xin-Ying He ◽  
Li Xiao
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Adverse Events ◽  
Randomized Clinical Trials ◽  
Meta Analysis ◽  
Localized Prostate Cancer ◽  
Hypofractionated Radiotherapy ◽  
Cancer Specific Survival ◽  
Conventional Radiotherapy ◽  
Results Of Treatment

Abstract Background Prostate cancer is one of the most common cancers in the world. The results of treatment after hypofractionated radiotherapy only have been reported from several small randomized clinical trials. Therefore, we conducted a meta-analysis to compare clinical outcomes of hypofractionated radiotherapy versus conventional radiotherapy in the treatment of intermediate- to high-risk localized prostate cancer. Methods Relevant studies were identified through searching related databases till August 2018. Hazard ratio (HR) or risk ratio (RR) with its corresponding 95% confidence interval (CI) was used as pooled statistics for all analyses. Results The meta-analysis results showed that overall survival (HR = 1.12, 95% CI: 0.93–1.35, p = 0.219) and prostate cancer-specific survival (HR = 1.29, 95% CI: 0.42–3.95, p = 0.661) were similar in two groups. The pooled data showed that biochemical failure was RR = 0.90, 95% CI: 0.76–1.07, p = 0.248. The incidence of acute adverse gastrointestinal events (grade ≥ 2) was higher in the hypofractionated radiotherapy (RR = 1.70, 95% CI: 1.12–2.56, p = 0.012); conversely, for late grade ≥ 2 gastrointestinal adverse events, a significant increase in the conventional radiotherapy was found (RR = 0.75, 95% CI: 0.61–0.91, p = 0.003). Acute (RR = 1.01, 95% CI: 0.89–1.15, p = 0.894) and late (RR = 0.98, 95% CI: 0.86–1.10, p = 0.692) genitourinary adverse events (grade ≥ 2) were similar for both treatment groups. Conclusion Results suggest that the efficacy and risk for adverse events are comparable for hypofractionated radiotherapy and conventional radiotherapy in the treatment of intermediate- to high-risk localized prostate cancer.

scholarly journals Undertreatment of High-Risk Localized Prostate Cancer in the California Latino Population

2018 ◽  
Vol 16 (11) ◽  
pp. 1353-1360 ◽  
Author(s):  
Daphne Y. Lichtensztajn ◽  
John T. Leppert ◽  
James D. Brooks ◽  
Sumit A. Shah ◽  
Weiva Sieh ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Localized Prostate Cancer ◽  
Latino Population
Sign in / Sign up

Export Citation Format

Share Document